Literature DB >> 16442295

Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.

Alice S Chen-Plotkin1, Ghazaleh Sadri-Vakili, George J Yohrling, Melissa W Braveman, Caroline L Benn, Kelly E Glajch, Derek P DiRocco, Laurie A Farrell, Dimitri Krainc, Silvia Gines, Marcy E MacDonald, Jang-Ho J Cha.   

Abstract

Huntington's disease (HD) is a neurodegenerative disease caused by expansion of a polyglutamine tract within the huntingtin protein. Transcriptional dysregulation has been implicated in HD pathogenesis; recent evidence suggests a defect in Sp1-mediated transcription. We used chromatin immunoprecipitation (ChIP) assays followed by real-time PCR to quantify the association of Sp1 with individual genes. We find that, despite normal protein levels and normal to increased overall nuclear binding activity, Sp1 has decreased binding to specific promoters of susceptible genes in transgenic HD mouse brain, in striatal HD cells, and in human HD brain. Genes whose mRNA levels are decreased in HD have abnormal Sp1-DNA binding, whereas genes with unchanged mRNA levels have normal levels of Sp1 association. Moreover, the altered binding seen with Sp1 is not found with another transcription factor, NF-Y. These findings suggest that mutant huntingtin dissociates Sp1 from target promoters, inhibiting transcription of specific genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442295     DOI: 10.1016/j.nbd.2005.11.001

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  52 in total

Review 1.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 2.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 3.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation.

Authors:  Mee-Ohk Kim; Prianka Chawla; Ryan P Overland; Eva Xia; Ghazaleh Sadri-Vakili; Jang-Ho J Cha
Journal:  J Neurosci       Date:  2008-04-09       Impact factor: 6.167

5.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

Review 6.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

7.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

8.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

9.  Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor.

Authors:  Tomoyuki Yamanaka; Haruko Miyazaki; Fumitaka Oyama; Masaru Kurosawa; Chika Washizu; Hiroshi Doi; Nobuyuki Nukina
Journal:  EMBO J       Date:  2008-02-21       Impact factor: 11.598

Review 10.  The role of amyloidogenic protein oligomerization in neurodegenerative disease.

Authors:  Gregor P Lotz; Justin Legleiter
Journal:  J Mol Med (Berl)       Date:  2013-03-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.